Compare Fabrinet (FN) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Tilray Brands Inc — how do they compare? Fabrinet trades at $459.99 (market cap $17.44B), while Tilray Brands Inc trades at $4.34 (market cap $541.36M). The key difference: Fabrinet is far larger — about 32.2× Tilray Brands Inc's market cap, and Fabrinet is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| FN | TLRY | |
|---|---|---|
Market Cap | $17.44B | $541.36M |
Sector | Technology | Health |
52-Week High | $746.47 | $21.00 |
52-Week Low | $277.04 | $4.31 |
Enterprise Value | $16.50B | $638.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $460.16, down 4.69% with a bearish technical signal despite strong fundamentals. The company reported consistent earnings beats with Q1 2026 EPS of $3.72 exceeding expectations, driven by 39% YoY revenue growth in optical communications. Analyst consensus remains strongly bullish with 18 buy ratings and a $733 price target, though technical indicators show selling pressure with support at $448.
The outlook remains positive given Fabrinet's strategic position in AI infrastructure and optical communications, with projected revenue growth to $4.2B in 2026. Key risks include premium valuation multiples and supply chain constraints, but the debt-free balance sheet and expanding margins support long-term growth potential in the AI-driven data center market.
TLRY trades at $4.36, down 0.57% on the day, amid a bearish technical signal and mixed quarterly earnings. The company reported a net loss of -$2.19 billion for 2025 despite revenue growth to $821 million, with a negative net income margin of -156.67%. Recent developments include medical cannabis expansion in Panama and the acquisition of HelloMD to enhance digital healthcare capabilities.
While low valuation ratios (P/S of 0.55, P/B of 0.35) suggest potential undervaluation, persistent losses and negative cash flow from operations pose significant risks. Analyst sentiment is cautious with a 'Hold' consensus, reflecting concerns over profitability despite growth initiatives. The stock's outlook hinges on achieving sustainable profitability and navigating competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
